抗丙型肝炎药物研究进展

The progress in anti-hepatitis C drugs

近些年来,丙型肝炎病毒(HCV)生物学的快速进展使人们对HCV的感染和复制有了突破性认识,对抗HCV药物的研究与开发产生了重要影响。HCV NS3/4蛋白抑制剂telaprevir和boceprevir的开发进入临床Ⅲ期试验,一些NS5B抑制剂也进入临床研究,在很好降低感染病人病毒载量的同时显示出较好的耐受性。另外,通过干预与HCV复制有关的宿主细胞蛋白进行抗HCV的研究也受到普遍关注,并取得众多突破。本文将着重介绍一些近年来以病毒蛋白为靶点及以细胞因子为靶点的抗HCV药物的研究进展。

In recent years, the development of the biology of HCV, has contributed breakthroughknowledge on the infection and replication of HCV, and makes an important impact on the development and reaearch of anti-hepatitis C viral drugs. Telaprevir and boceprevir, which belong to NS3/4 protease inhibitor, have reached Phase III. Several classes of small-molecule inhibitors of HCV NS5B have progressed into clinical development and demonstrated efficacy in reducing viral load in infected patients, and are well-tolerant. In addition, it also has been concerned about anti-HCV research by interfering with host cell proteins related to HCV replication, and made numerous breakthroughs. This paper describes an overview of the progress in the anti-HCV drugs targeting the virus protein and cytokines.